Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia
Clinical trial NCT06366789 · RECRUITING
Trial details
- NCT number
- NCT06366789
- Sponsor
- Lomond Therapeutics Holdings, Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-29
- Primary completion
- 2026-01-01
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.